Therapy of male osteoporosis with parathyroid hormone

What Was Tested

The paper reports a study of Parathyroid Hormone (PTH 1-84), published as a randomized controlled trial.

Those for whom no etiology is readily apparent are said to have primary or idiopathic male osteoporosis.

In these individuals, histomorphometric studies indicate that this is a disorder that is more typically characterized by low turnover.

Who Took Part

The age groups tagged for this paper are adults, middle-aged adults and older adults, men only.

Twenty-three men, 30-68 years old (50 +/- 1.9) with Z-scores less than -2.0 were assigned to a placebo (n = 13) or treatment (n = 10) arm.

How the Study Was Run

The design is described as randomized, double-blind, open-label and placebo-controlled.

The participants were allocated by chance, so the Parathyroid Hormone (PTH 1-84) group and the comparison group should start out alike.

As a double-blind Parathyroid Hormone (PTH 1-84) study, the assignments were hidden from both participants and investigators until the end.

Everyone knew when Parathyroid Hormone (PTH 1-84) was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

The comparison arm used a placebo, so changes seen with Parathyroid Hormone (PTH 1-84) could be set against what happens without it.

What Was Measured

Those for whom no etiology is readily apparent are said to have primary or idiopathic male osteoporosis.

The subject headings attached to it are Bone Density, Bone Resorption, Bone and Bones, Climacteric, Osteogenesis, Osteoporosis and Parathyroid Hormone.

What This Means in Plain Language

The paper is a randomized, double-blind and open-label study of Parathyroid Hormone (PTH 1-84).

The publication is from 2001 (Calcified tissue international), a journal based in United States.

More context: the Parathyroid Hormone (PTH 1-84) compound page, all human trials.